NCT02639247 - Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor | Biotech Hunter

Enrollment

333

Participants

Timeline

Start Date

December 23, 2015

Primary Completion Date

October 5, 2016

Study Completion Date

January 18, 2017

Conditions

Hepatitis C Virus Infection

Interventions

DRUG

SOF/VEL/VOX

400/100/100 mg FDC tablet administered orally once daily with food

DRUG

SOF/VEL

400/100 mg FDC tablet administered orally once daily without regard to food

Trial Locations (78)

Unknown

Long Beach

Los Angeles

Palo Alto

Pasadena

Rialto

San Diego

San Francisco

Aurora

Englewood

Washington D.C.

Gainesville

Miami

Orlando

Wellington

Atlanta

Marietta

Chicago

Indianapolis

Bastrop

Baltimore

Catonsville

Boston

Ann Arbor

Detroit

Kansas City

St Louis

Hillsborough

New York

Asheville

Fayetteville

Philadelphia

Pittsburgh

Providence

Germantown

Nashville

Houston

San Antonio

Murray

Falls Church

Norfolk

Richmond

Seattle

Madison

Camperdown

Darlinghurst

Herston

Clayton

Melbourne

Calgary

Edmonton

Vancouver

Brampton

Ottawa

Toronto

Clermont-Ferrand

Clichy

Grenoble

Lille

Limoges

Lyon

Marseille

Montpellier

Nice

Paris

Pessac

Toulouse

Vandœuvre-lès-Nancy

Villejuif

Berlin

Bonn

Cologne

Frankfurt am Main

Hamburg

Hanover

Grafton

San Juan

London

Oxford